donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

SUPN Supernus Pharmaceuticals

32.790
+1.530+4.89%
Close 08/12 16:00 ET
32.79000.00%
Post Mkt Price 08/12 16:14 ET
High
32.790
Open
31.430
Turnover
16.54M
Low
31.060
Pre Close
31.260
Volume
512.50K
Market Cap
1.75B
P/E(TTM)
32.47
52wk High
34.500
Shares
53.50M
P/E(Static)
33.46
52wk Low
23.150
Float Cap
1.58B
Bid/Ask %
0.00%
Historical High
61.250
Shs Float
48.27M
Volume Ratio
1.05
Historical Low
4.300
Dividend TTM
--
Div Yield TTM
2000
P/B
2.08
Dividend LFY
--
Div Yield LFY
6099.42%
Turnover Ratio
1.06%
Amplitude
5.53%
Avg Price
32.269
Lot Size
1
Float Cap
1.58B
Bid/Ask %
0.00%
Historical High
61.250
Shs Float
48.27M
Volume Ratio
1.05
Historical Low
4.300
Dividend TTM
--
P/B
2.08
Dividend LFY
--
Turnover Ratio
1.06%
Amplitude
5.53%
Avg Price
32.269
Lot Size
1
Price Forecast

No Data

News

Comment

Sign in to post a comment

No comment yet

Company Overview More
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company’s commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson’s Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
CEO: Khattar, Jack A.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...